玻璃体内地塞米松植入剂与雷珠单抗治疗脉络膜黑色素瘤近距离放疗继发黄斑水肿的对比
本研究比较玻璃体内地塞米松(Dex)植入剂0.7 mg与玻璃体内雷珠单抗(Ra)治疗脉络膜黑色素瘤敷贴近距离放疗继发放射性黄斑病变伴黄斑水肿的疗效。Ra组8例、Dex组8例,两组末次随访视力均较基线显著提高,黄斑中心凹厚度均显著下降;Dex组所需注射次数更少。两组均无患者出现显著白内障或高眼压。
要点
- Ra组与Dex组末次随访视力均较基线显著提高,黄斑中心凹厚度均显著下降。
- Dex组平均注射2.1±0.8次,Ra组平均注射7.8±3.9次,Dex组所需注射次数更少。
- 两组均无患者出现显著白内障或高眼压。
核心结论
- Ra与Dex均为敷贴近距离放疗治疗葡萄膜黑色素瘤后继发黄斑水肿的有效治疗。
- 接受Dex治疗的患者达到解剖和功能改善所需注射次数更少。
研究设计与样本
- 比较玻璃体内地塞米松植入剂0.7 mg与玻璃体内雷珠单抗治疗脉络膜黑色素瘤敷贴近距离放疗继发放射性黄斑病变伴黄斑水肿的疗效。
- 8例患者接受玻璃体内雷珠单抗治疗,8例患者接受地塞米松玻璃体内植入剂治疗。
- 采用谱域光学相干断层扫描评估视力与黄斑中心凹厚度。
主要发现
- 两组黄斑中心凹平均计算照射剂量及从近距离放疗至黄斑病变发展的平均时间均无显著差异。
- Ra组平均注射7.8±3.9次,平均随访33±15个月(范围7-52个月)。
- Dex组平均注射2.1±0.8次,平均随访22±7个月(范围11-31个月)。
- 两组平均视力从基线至末次随访均显著提高。
- 黄斑中心凹厚度从基线至末次随访在Ra组由459±81 μm降至243±58 μm、在Dex组由437±71 μm降至254±44 μm,两组均显著下降。
临床怎么用
- 原文结论认为Ra与Dex均为敷贴近距离放疗治疗葡萄膜黑色素瘤后继发黄斑水肿的有效治疗。
- 原文结论指出接受Dex治疗的患者达到解剖和功能改善所需注射次数更少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy of an intravitreal dexamethasone (Dex) implant 0.7 mg compared with intravitreal ranibizumab (Ra) for the treatment of radiation maculopathy with macular edema secondary to plaque brachytherapy in choroidal melanoma. METHODS: Eight patients were treated with intravitreal Ra, and eight patients received the Dex intravitreal implant. Visual acuity and foveal thickness were evaluated using spectral domain optical coherence tomography. RESULTS: The mean calculated irradiation to the fovea and mean times from brachytherapy to maculopathy development did not differ significantly between groups. In the Ra group, a mean 7.8 ± 3.9 injections were given and the mean follow-up was 33 ± 15 months (range, 7-52 months). In the Dex group, a mean 2.1 ± 0.8 injections were given and the mean follow-up was 22 ± 7 months (range, 11-31 months). The mean visual acuity improved significantly from the baseline to the last follow-up visit in both groups. Foveal thickness decreased significantly in both groups from 459 ± 81 μm to 243 ± 58 μm and from 437 ± 71 μm to 254 ± 44 μm from the baseline to the last follow-up visit in the Ra and Dex groups, respectively. No patients developed significant cataract or ocular hypertension in both groups. CONCLUSION: Both Ra and Dex are effective treatments for macular edema secondary to plaque brachytherapy for uveal melanoma. Dex-treated patients required fewer injections to achieve anatomical and functional improvement.
引用
- Russo A, Reibaldi M, Avitabile T, et al. DEXAMETHASONE INTRAVITREAL IMPLANT VS RANIBIZUMAB IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRACHYTHERAPY FOR CHOROIDAL MELANOMA. Retina. 2018. PMID: 28272283. doi:10.1097/IAE.0000000000001585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。